Effect of NF-κB inhibitors on the chemotherapy-induced apoptosis of the colon cancer cell line HT-29

Experimental and Therapeutic Medicine

Volumn 4, Issue 4, 2012, Pages 716-722

  Liu, Ting ^a   Liu, Dan ^a   Liu, Jing ^a   Song, Ji Tao ^a   Gao, Shan Ling ^a   Li, Hui ^a   Hu, Li Hong ^a   Liu, Bing Rong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Chemotherapy; Colon cancer; NF B inhibitor; Pyrrolidine dithiocarbamate; SN50

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; ARSENIC ACID; BORTEZOMIB; FLUOROURACIL; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXALIPLATIN; PACLITAXEL; PYRROLIDINE DITHIOCARBAMATE; SN 50; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG INHIBITION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOASSAY; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84865386840     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.647     Document Type: Article

References (24)

1. Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46: 705-716, 1986.
2. Zandi E and Karin M: Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. Mol Cell Biol 19: 4547-4551, 1999.
3. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 3: 241-246, 2001.
4. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
5. Wang CY, Guttridge DC, Mayo MW and Baldwin AS Jr: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19: 5923-5929, 1999.
6. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and BaldwinASJr: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
7. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
8. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC and TreonSP: Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99: 2162-2171, 2002.
9. Poynter JN, Haile RW, Siegmund KD, Campbell PT, FigueiredoJC, Limburg P, Young J, Le Marchand L, Potter JD, Cotterchio M, Casey G, Hopper JL, Jenkins MA, ThibodeauSN, Newcomb PA and Baron JA; Colon Cancer Family Registry: Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 18: 2745-2750, 2009.
10. Bostick RM, Potter JD, Kushi LH, Sellers TA, Steinmetz KA, McKenzie DR, Gapstur SM and Folsom AR: Sugar, meat and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women. Cancer Causes Control 5: 38-52, 1994.
11. Chan AT and Giovannucci EL: Primary prevention of colorectal cancer. Gastroenterology 138: 2029-2043, 2010.
12. Kim HJ, Hawke N and Baldwin AS: NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 13: 738-747, 2006.
13. Legrand-Poels S, Schoonbroodt S, Matroule JY and Piette J: NF-kappaB: an important transcription factor in photobiology. Photochem Photobiol B 45: 1-8, 1998.
14. Romano MF, Lamberti A, Bisogni R, Tassone P, Pagnini D, Storti G, Del Vecchio L, Turco MC and Venuta S: Enhancement of cytosine arabinoside induced apoptosis in human myeloblastic leukemia cells by NF kappaB/Rel-specific decoy oligodeoxynucleotides. Gene Ther 7: 1234-1237, 2000.
15. Beg AA, Sha WC, Bronson RT, Ghosh S and Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappaB. Nature 376: 167-170, 1995.
16. Holmes-McNary M and Baldwin AS Jr: Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of IkappaB kinase. Cancer Res 60: 3477-3483, 2000.
17. Yemelyanov A, Gasparian A, Lindholm P, Dang L, Pierce JW, Kisseljov F, Karseladze A and Budunova I: Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25: 387-398, 2006.
18. Wu LF, Li GP, Su JD, Pu ZJ, Feng JL, Ye YQ and Wei BL: Involvement of NF-kappaB activation in the apoptosis induced by extracellular adenosine in human hepatocellular carcinoma HepG2 cells. Biochem Cell Biol 88: 705-714, 2010.
19. Furuta H, Osawa K, Shin M, Ishikawa A, Matsuo K, Khan M, AokiK, Ohya K, Okamoto M, Tominaga K, et al: Selective inhibition of NF-κB suppresses bone invasion by oral squamous cell carcinoma in vivo. Int J Cancer: Jan 19, 2012 (Epub ahead of print).
20. Zhu BS, Xing CG, Lin F, Fan XQ, Zhao K and Qin ZH: Blocking NF-κB nuclear translocation leads to p53-related autophagy activation and cell apoptosis. World J Gastroenterol 17: 478-487, 2011.
21. Si X, McManus BM, Zhang JC, Yuan J, Cheung C, EsfandiareiM, Suarez A, Morgan A and Luo HL: Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 79: 8014-8023, 2005.
22. Caravita T, de Fabritiis P, Palumbo A, Amadori S and BoccadoroM: Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 3: 374-387, 2006.
23. Nencioni A, Grünebach F, Patrone F, Ballestrero A and BrossartP: Proteasome inhibitors: antitumor effects and beyond. Leukemia 21: 30-36, 2007.
24. Orange JS and May MJ: Cell penetrating peptide inhibitors of nuclear factor-kappaB. Cell Mol Life Sci 65: 3564-3591, 2008.